Therapeutic opportunities in dengue infection

Drug Development Research

Volumn 72, Issue 6, 2011, Pages 480-500

  Fagundes, Caio T ^a   Costa, Vivian V ^a   Cisalpino, Daniel ^a   Souza, Danielle G ^a   Teixeira, Mauro M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

animal models; antiviral; Dengue; inflammation; therapeutics

Indexed keywords

1 DEOXYNOJIRIMYCIN DERIVATIVE; 7 DEAZA 2' C METHYLADENOSINE; ANTIVIRUS AGENT; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; DASATINIB; MEVINOLIN; MORPHOLINE DERIVATIVE; N NONYLDEOXYNOJIRIMYCIN; NITD 008; PI 88; UNCLASSIFIED DRUG;

ARTICLE; DENGUE; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EXPERIMENTAL MODEL; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; TROPICAL DISEASE; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS;

EID: 80053001605     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20455     Document Type: Article

References (185)

1. Alves-Filho JC, Spiller F, Cunha FQ,. 2010. Neutrophil paralysis in sepsis. Shock 34 (Suppl 1): 15-21.
2. + T cells have both protective and pathogenic roles in dengue virus infection. Immunol Lett 95: 167-174. (Pubitemid 39237662)
3. An J, Kimura-Koroda J, Hurabayashi Y, Yasui K,. 1999. Development of a novel mouse model for dengue virus infection. Virology 263: 70-77. (Pubitemid 29493619)
4. Arjona A, Foellmer HG, Town T, Leng L, McDonald C, Wang T, Wong SJ, Montgomery RR, Fikrig E, Bucala R,. 2007. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 117: 3059-3066. (Pubitemid 47529635)
5. Assunção-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, Souza DG, Pacheco P, Barbosa-Lima G, Gomes RN, Bozza PT, et al. 2009. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J 24: 218-228.
6. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G,. 2003. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 35: 33-42. (Pubitemid 36173502)
7. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K, Jairungsri A, Kanlaya R, Tangthawornchaikul N, Puttikhunt C, et al. 2006. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 193: 1078-1088.
8. Bach TL, Barsigian C, Chalupowicz DG, Busler D, Yaen CH, Grant DS, Martinez J,. 1998. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res 238: 324-334. (Pubitemid 28372819)
9. Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL,. 1999. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA 96: 9792-9796. (Pubitemid 29398811)
10. Balmaseda A, Hammond SN, Tellez Y, Imhoff L, Rodriguez Y, Saborio SI, Mercado JC, Perez L, Videa E, Almanza E, et al. 2006. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Trop Med Int Health 11: 935-942. (Pubitemid 43846454)
11. Balmaseda A, Saborio S, Tellez Y, Mercado JC, Perez L, Hammond SN, Rocha C, Kuan G, Harris E,. 2008. Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. J Clin Virol 43: 287-291.
12. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E,. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.
13. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R,. 2005. Dengue fever in humanized NOD/SCID mice. J Virol 79: 13797-13799. (Pubitemid 41508191)
14. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R,. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759. (Pubitemid 23339882)
15. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, et al. 2007. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587-596. (Pubitemid 46828480)
16. Binh PT, Matheus S, Huong VT, Deparis X, Marechal V,. 2009. Early clinical and biological features of severe clinical manifestations of dengue in Vietnamese adults. J Clin Virol 45: 276-280.
17. Blaney Jr JE, Johnson DH, Manipon GG, Firestone CY, Hanson CT, Murphy BR, Whitehead SS,. 2002. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300: 125-139.
18. Blaney Jr JE, Matro JM, Murphy BR, Whitehead SS,. 2005. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79: 5516-5528. (Pubitemid 40548220)
19. Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, Bozza PT, Kubelka CF,. 2008. Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis 8: 86.
20. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT,. 2004. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22: 309-313. (Pubitemid 39480698)
21. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR,. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189: 341-346. (Pubitemid 29063255)
22. Bressanelli S, Stiasny K, Allison SL, Stura EA, Duquerroy S, Lescar J, Heinz FX, Rey FA,. 2004. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 23: 728-738. (Pubitemid 38425440)
23. Brinton MA,. 2002. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol 56: 371-402. (Pubitemid 35217460)
24. Brown KL, Cosseau C, Gardy JL, Hancock RE,. 2007. Complexities of targeting innate immunity to treat infection. Trends Immunol 28: 260-266. (Pubitemid 46824085)
25. Burke DS, Nisalak A, Johnson DE, Scott RM,. 1988. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38: 172-180. (Pubitemid 18036130)
26. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R,. 1995. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71.
27. Calandra T, Roger T,. 2003. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3: 791-800. (Pubitemid 37328657)
28. Calvert AE, Huang CY, Kinney RM, Roehrig JT,. 2006. Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J Gen Virol 87: 339-346. (Pubitemid 43169260)
29. Carroll SS, Olsen DB,. 2006. Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets 6: 17-29. (Pubitemid 43796633)
30. Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, Davies ME, MacCoss M, Hazuda D, Olsen DB,. 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 53: 926-934.
31. Chambers TJ, Grakoui A, Rice CM,. 1991. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol 65: 6042-6050.
32. Chaturvedi UC, Nagar R,. 2008. Dengue and dengue haemorrhagic fever: Indian perspective. J Biosci 33: 429-441.
33. Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA,. 2007. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol 81: 5518-5526. (Pubitemid 46846992)
34. Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, Lin YS, Wang ST, Shyu HW, Yeh TM,. 2006. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 74: 142-147.
35. Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY, Lee CK, Chiou TW, Wong CH, Hsieh SL,. 2008. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453: 672-676.
36. Chu JJ, Yang PL,. 2007. c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc Natl Acad Sci USA 104: 3520-3525. (Pubitemid 46364191)
37. Clyde K, Kyle JL, Harris E,. 2006. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 80: 11418-11431. (Pubitemid 44788858)
38. Conceicao TM, El-Bacha T, Villas-Boas CS, Coello G, Ramirez J, Santoro AB, Montero-Lomelí M, Da Poian AT,. 2010. Gene expression analysis during dengue virus infection in HepG2 cells reveals virus control of innate immune response. J Infect 60: 65-75.
39. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Despres P,. 2000. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol 74: 564-572. (Pubitemid 30002943)
40. Couvelard A, Marianneau P, Bedel C, Drouet MT, Vachon F, Henin D, Deubel V,. 1999. Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Hum Pathol 30: 1106-1110. (Pubitemid 29427169)
41. Deen JL, Harris E, Wills B, Balmaseda A, Hammond SN, Rocha C, Dung NM, Hung NT, Hien TT, Farrar JJ,. 2006. The WHO dengue classification and case definitions: time for a reassessment. Lancet 368: 170-173. (Pubitemid 43994174)
42. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E,. 2000. Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 74: 4957-4966. (Pubitemid 30313834)
43. Diaz FJ, Black WC, Farfan-Ale JA, Lorono-Pino MA, Olson KE, Beaty BJ,. 2006. Dengue virus circulation and evolution in Mexico: a phylogenetic perspective. Arch Med Res 37: 760-773. (Pubitemid 43975170)
44. Dong H, Zhang B, Shi PY,. 2008. Flavivirus methyltransferase: a novel antiviral target. Antiviral Res 80: 1-10.
45. Durantel D,. 2009. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Invest Drugs 10: 860-870.
46. Elshuber S, Allison SL, Heinz FX, Mandl CW,. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol 84: 183-191. (Pubitemid 36113564)
47. Endy TP, Chunsuttiwat S, Nisalak A, Libraty DH, Green S, Rothman AL, Vaughn DW, Ennis FA,. 2002. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 156: 40-51. (Pubitemid 34680622)
48. Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U,. 2006. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 13: 372-373. (Pubitemid 43873510)
49. Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick R,. 1998. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 44 (8 Pt 2): 1845-1853. (Pubitemid 28368905)
50. Garcia CC, Guabiraba R, Soriani FM, Teixeira MM,. 2010a. The development of anti-inflammatory drugs for infectious diseases. Discov Med 25 (4): 559-567.
51. Garcia CC, Russo RC, Guabiraba R, Fagundes CT, Polidoro RB, Tavares LP, Salgado AP, Cassali GD, Sousa LP, Machado AV, Teixeira MM,. 2010b. Platelet-activating factor receptor plays a role in lung injury and death caused by influenza A in mice. PLoS Pathog 6: e1001171.
52. Garcia JG, Davis HW, Patterson CE,. 1995. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell Physiol 163: 510-522.
53. Gibbons RV, Vaughn DW,. 2002. Dengue: an escalating problem. BMJ 324: 1563-1566. (Pubitemid 34713137)
54. Glass WG, Rosenberg HF, Murphy PM,. 2003. Chemokine regulation of inflammation during acute viral infection. Curr Opin Allergy Clin Immunol 3: 467-473. (Pubitemid 39149560)
55. 2-terminal portions of the fibrin beta chains. Biochemistry 41: 4107-4116. (Pubitemid 34251050)
56. Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, Ma'roef C, Erlin, Sutaryo, Porter KR, Halstead SB,. 1999. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia. I. Studies in 1995-1996. Am J Trop Med Hyg 61: 412-419. (Pubitemid 29428712)
57. Groger M, Pasteiner W, Ignatyev G, Matt U, Knapp S, Atrasheuskaya A, Bukin E, Friedl P, Zinkl D, Hofer-Warbinek R, et al. 2009. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One 4: e5391.
58. Gromowski GD, Barrett ND, Barrett AD,. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82: 8828-8837.
59. Guabiraba R, Marques RE, Besnard AG, Fagundes CT, Souza DG, Ryffel B, Teixeira MM,. 2010. Role of chemokines receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice. PLoS One 5 (12): e15680.
60. Gu B, Mason P, Wang L, Norton P, Bourne N, Moriarty R, Mehta A, Despande M, Shah R, Block T,. 2007. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir Chem Chemother 18: 49-59. (Pubitemid 46426937)
61. Guzman MG, Kouri G,. 2002. Dengue: an update. Lancet Infect Dis 2: 33-42. (Pubitemid 36109304)
62. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB,. 2002. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publ 11: 223-227. (Pubitemid 34555771)
63. Halstead SB,. 2007. Dengue. Lancet 370: 1644-1652. (Pubitemid 350052290)
64. Halstead SB, Nimmannitya S, Cohen SN,. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42: 311-328.
65. Hammon WM, Rudnick A, Sather GE,. 1960. Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 131: 1102-1103.
66. Heaton NS, Randall G,. 2010. Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe 8: 422-432.
67. Horuk R, Proudfoot AE,. 2009. Drug discovery targeting the chemokine system - where are we? Front Biosci (Elite Ed) 1: 209-219.
68. Hotta H, Murakami I, Miyasaki K, Takeda Y, Shirane H, Hotta S,. 1981. Inoculation of dengue virus into nude mice. J Gen Virol 52: 71-76. (Pubitemid 11189685)
69. Hrobowski YM, Garry RF, Michael SF,. 2005. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2: 49.
70. Huang KJ, Li SY, Chen SC, Liu HS, Lin YS, Yeh TM, Liu CC, Lei HY,. 2000. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol 81: 2177-2182.
71. Ishii S, Shimizu T,. 2000. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 39: 41-82. (Pubitemid 30145442)
72. Jessie K, Fong MY, Devi S, Lam SK, Wong KT,. 2004. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 189: 1411-1418. (Pubitemid 38543590)
73. Johnson AJ, Roehrig JT,. 1999. New mouse model for dengue virus vaccine testing. J Virol 73: 783-786. (Pubitemid 28565427)
74. Khakpoor A, Panyasrivanit M, Wikan N, Smith DR,. 2009. A role for autophagolysosomes in dengue virus 3 production in HepG2 cells. J Gen Virol 90: 1093-1103.
75. Kimura K, Nagaki M, Nishihira J, Satake S, Kuwata K, Moriwaki H,. 2006. Role of macrophage migration inhibitory factor in hepatitis B virus-specific cytotoxic-T-lymphocyte-induced liver injury. Clin Vaccine Immunol 13: 415-419.
76. Kouri GP, Guzman MG, Bravo JR, Triana C,. 1989. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ 67: 375-380. (Pubitemid 19248539)
77. Krishnan MN, Sukumaran B, Pal U, Agaisse H, Murray JL, Hodge TW, Fikrig E,. 2007. Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol 81: 4881-4885. (Pubitemid 46668686)
78. Kuitert LM, Angus RM, Barnes NC, Barnes PJ, Bone MF, Chung KF, Fairfax AJ, Higenbotham TW, O'Connor BJ, Piotrowska B, et al. 1995. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med 151: 1331-1335.
79. Kurane I, Ennis FE,. 1992. Immunity and immunopathology in dengue virus infections. Semin Immunol 4: 121-127.
80. -/- (RAG-hu) mice. Virology 369: 143-152. (Pubitemid 350029864)
81. Kyle JL, Harris E,. 2008. Global spread and persistence of dengue. Annu Rev Microbiol 62: 71-92.
82. Kyle JL, Beatty PR, Harris E,. 2007. Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis 195: 1808-1817. (Pubitemid 46870254)
83. Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Najera I,. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 61: 1205-1216. (Pubitemid 351753583)
84. Lee CJ, Lin HR, Liao CL, Lin YL,. 2008. Cholesterol effectively blocks entry of flavivirus. J Virol 82: 6470-6480.
85. Lee E, Pavy M, Young N, Freeman C, Lobigs M,. 2006. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res 69: 31-38. (Pubitemid 41790479)
86. Lee YR, Liu MT, Lei HY, Liu CC, Wu JM, Tung YC, Lin YS, Yeh TM, Chen SH, Liu HS,. 2006. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol 87: 3623-3630. (Pubitemid 44816994)
87. Lee YR, Lei HY, Liu MT, Wang JR, Chen SH, Jiang-Shieh YF, Lin YS, Yeh TM, Liu CC, Liu HS,. 2008. Autophagic machinery activated by dengue virus enhances virus replication. Virology 374: 240-248.
88. Liao M, Kielian M,. 2005. Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J Cell Biol 171: 111-120. (Pubitemid 41434606)
89. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG,. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319: 1830-1834. (Pubitemid 351451591)
90. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, Chansiriwongs W, Vaughn DW, Nisalak A, Ennis FA, Rothman AL,. 2002. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185: 1213-1221. (Pubitemid 34439127)
91. Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, Huang YY, Huang YL, Kao CL, King CC,. 1998. Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 72: 9729-9737.
92. Lindenbach BD, Pragai BM, Montserret R, Beran RK, Pyle AM, Penin F, Rice CM,. 2007. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. J Virol 81: 8905-8918. (Pubitemid 47311435)
93. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG,. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15: 312-317. (Pubitemid 351654038)
94. Lorenz IC, Kartenbeck J, Mezzacasa A, Allison SL, Heinz FX, Helenius A,. 2003. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol 77: 4370-4382. (Pubitemid 36350974)
95. Luo D, Xu T, Watson RP, Scherer-Becker D, Sampath A, Jahnke W, Yeong SS, Wang CH, Lim SP, Strongin A, Vasudevan SG, Lescar J,. 2008. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J 27: 3209-3219.
96. Mackenzie J,. 2005. Wrapping things up about virus RNA replication. Traffic 6: 967-977.
97. Mackenzie JM, Jones MK, Westaway EG,. 1999. Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells. J Virol 73: 9555-9567. (Pubitemid 29487111)
98. Mackenzie JM, Westaway EG,. 2001. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 75: 10787-10799. (Pubitemid 33031548)
99. Mackenzie JS, Gubler DJ, Petersen LR,. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: S98-S109. (Pubitemid 40018233)
100. Malet H, Masse N, Selisko B, Romette JL, Alvarez K, Guillemot JC, Tolou H, Yap TL, Vasudevan S, Lescar J, Canard B,. 2008. The flavivirus polymerase as a target for drug discovery. Antiviral Res 80: 23-35.
101. Mancini EJ, Assenberg R, Verma A, Walter TS, Tuma R, Grimes JM, Owens RJ, Stuart DI,. 2007. Structure of the Murray Valley encephalitis virus RNA helicase at 1.9 Angstrom resolution. Protein Sci 16: 2294-2300. (Pubitemid 47481665)
102. Mantovani A,. 1999. The chemokine system: redundancy for robust outputs. Immunol Today 20: 254-257. (Pubitemid 29258161)
103. Martins S, Ramos MJ, Fernandes PA,. 2008. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem 15: 1083-1095. (Pubitemid 352002977)
104. McCown M, Diamond MS, Pekosz A,. 2003. The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 313: 514-524. (Pubitemid 37045358)
105. Medin CL, Fitzgerald KA, Rothman AL,. 2005. Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J Virol 79: 11053-11061. (Pubitemid 41170646)
106. Menendez-Arias L,. 2010. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res 85: 210-231.
107. Messer WB, Vitarana UT, Sivananthan K, Elvtigala J, Preethimala LD, Ramesh R, Withana N, Gubler DJ, De Silva AM,. 2002. Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. Am J Trop Med Hyg 66: 765-773. (Pubitemid 35001053)
108. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM,. 2003. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 9: 800-809. (Pubitemid 36801579)
109. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, et al. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278: 49164-49170.
110. Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S,. 2008. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog 4: e17.
111. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R,. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 99: 345-350. (Pubitemid 34060365)
112. Mitchell RA, Metz CN, Peng T, Bucala R,. 1999. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274: 18100-18106.
113. Modis Y, Ogata S, Clements D, Harrison SC,. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100: 6986-6991. (Pubitemid 36706380)
114. Modis Y, Ogata S, Clements D, Harrison SC,. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427: 313-319. (Pubitemid 38133652)
115. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, et al. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9: 921-927. (Pubitemid 36889936)
116. Mosier DE,. 1990. Immunodeficient mice xenografted with human lymphoid cells: new models for in vivo studies of human immunobiology and infectious diseases. J Clin Immunol 10: 185-191. (Pubitemid 20258682)
117. Mosier DE,. 1996. Evaluation of protective immunity to HIV-1 in human PBL-SCID mice. Antibiot Chemother 48: 125-130.
118. Murgue B, Roche C, Chungue E, Deparis X,. 2000. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 60: 432-438. (Pubitemid 30127315)
119. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, Virelizier JL, Arenzana-Seisdedos F, Despres P,. 2003. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4: 723-728. (Pubitemid 36974759)
120. Navarro-Sanchez E, Despres P, Cedillo-Barron L,. 2005. Innate immune responses to dengue virus. Arch Med Res 36: 425-435. (Pubitemid 41140044)
121. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY,. 2010. Strategies for development of Dengue virus inhibitors. Antiviral Res 85: 450-462.
122. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11: 522-530. (Pubitemid 40685975)
123. Paes MV, Pinhao AT, Barreto DF, Costa SM, Oliveira MP, Nogueira AC, Takiya CM, Farias-Filho JC, Schatzmayr HG, Alves AM, Barth OM,. 2005. Liver injury and viremia in mice infected with dengue-2 virus. Virology 338: 236-246. (Pubitemid 41024860)
124. Paiva CN, Arras RH, Magalhaes ES, Alves LS, Lessa LP, Silva MH, Ejzemberg R, Canetti C, Bozza MT,. 2009. Migration inhibitory factor (MIF) released by macrophages upon recognition of immune complexes is critical to inflammation in Arthus reaction. J Leukoc Biol 85: 855-861.
125. Panyasrivanit M, Khakpoor A, Wikan N, Smith DR,. 2009. Linking dengue virus entry and translation/replication through amphisomes. Autophagy 5: 434-435.
126. Pastorino B, Nougairede A, Wurtz N, Gould E, de Lamballerie X,. 2010. Role of host cell factors in flavivirus infection: implications for pathogenesis and development of antiviral drugs. Antiviral Res 87: 281-294.
127. Pauwels F, Mostmans W, Quirynen LM, van der Helm L, Boutton CW, Rueff AS, Cleiren E, Raboisson P, Surleraux D, Nyanguile O, Simmen KA,. 2007. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J Virol 81: 6909-6919. (Pubitemid 46986627)
128. Petzelbauer P, Zacharowski PA, Miyazaki Y, Friedl P, Wickenhauser G, Castellino FJ, Groger M, Wolff K, Zacharowski K,. 2005. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 11: 298-304. (Pubitemid 40460558)
129. Poh MK, Yip A, Zhang S, Priestle JP, Ma NL, Smit JM, Wilschut J, Shi PY, Wenk MR, Schul W,. 2009. A small molecule fusion inhibitor of dengue virus. Antiviral Res 84: 260-266.
130. Reddy RC, Standiford TJ,. 2010. Effects of sepsis on neutrophil chemotaxis. Curr Opin Hematol 17: 18-24.
131. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, Boshell J, de Mesa MT, Nogueira RM, da Rosa AT,. 1997. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230: 244-251. (Pubitemid 27211855)
132. Roesner JP, Petzelbauer P, Koch A, Mersmann J, Zacharowski PA, Boehm O, Reingruber S, Pasteiner W, Mascher D, Wolzt M, et al. 2007. The fibrin-derived peptide Bbeta15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury. Crit Care Med 35: 1730-1735. (Pubitemid 46985877)
133. Roger T, David J, Glauser MP, Calandra T,. 2001. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414: 920-924. (Pubitemid 34024744)
134. Rothman AL, Ennis FA,. 1999. Immunopathogenesis of Dengue hemorrhagic fever. Virology 257: 1-6. (Pubitemid 29391794)
135. Rothwell C, Lebreton A, Young Ng C, Lim JY, Liu W, Vasudevan S, Labow M, Gu F, Gaither LA,. 2009. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 389: 8-19.
136. Russo RC, Garcia CC, Teixeira MM,. 2010. Anti-inflammatory drug development: Broad or specific chemokine receptor antagonists? Curr Opin Drug Discov Devel 13: 414-427.
137. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB,. 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653-669. (Pubitemid 15210730)
138. Sayce AC, Miller JL, Zitmann N,. 2010. Targeting a host process as an antiviral approach against dengue virus. Trends Microbiol 18: 323-330.
139. Schnittler HJ, Feldmann H,. 2003. Viral hemorrhagic fever - a vascular disease? Thromb Haemost 89: 967-972. (Pubitemid 36798147)
140. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG,. 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 195: 665-674.
141. Seneviratne SL, Malavige GN, de Silva HJ,. 2006. Pathogenesis of liver involvement during dengue viral infections. Trans R Soc Trop Med Hyg 100: 608-614.
142. Shresta S, Kyle JL, Robert Beatty P, Harris E,. 2004a. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 319: 262-273. (Pubitemid 38251267)
143. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E,. 2004b. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78: 2701-2710. (Pubitemid 38314329)
144. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E,. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208-10217. (Pubitemid 44522614)
145. Sierra B, Perez AB, Vogt K, Garcia G, Schmolke K, Aguirre E, Alvarez M, Volk HD, Guzman MG,. 2010. MCP-1 and MIP-1alpha expression in a model resembling early immune response to dengue. Cytokine 52: 175-183.
146. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, et al. 2008. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 198: 1337-1344.
147. Souza DG, Fagundes CT, Sousa LP, Amaral FA, Souza RS, Souza AL, Kroon EG, Sachs D, Cunha FQ, Bukin E, et al. 2009. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci USA 106: 14138-14143.
148. Spain-Santana TA, Marglin S, Ennis FA, Rothman AL,. 2001. MIP-1 alpha and MIP-1 beta induction by dengue virus. J Med Virol 65: 324-330.
149. Speyer CL, Gao H, Rancilio NJ, Neff TA, Huffnagle GB, Sarma JV, Ward PA,. 2004. Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol 165: 2187-2196. (Pubitemid 39578395)
150. Sprong T, Pickkers P, Geurts-Moespot A, van der Ven-Jongekrijg J, Neeleman C, Knaup M, Leroy D, Calandra T, van der Meer JW, Sweep F, van Deuren M,. 2007. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock 27: 482-487. (Pubitemid 46626074)
151. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L, Nithipanya N, Kalayanarooj S, Nisalak A, Thomas SJ, Gibbons RV, Mammen Jr MP, et al. 2007. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J 26: 283-290; discussion 291-282. (Pubitemid 46596649)
152. Stadler K, Allison SL, Schalich J, Heinz FX,. 1997. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 71: 8475-8481. (Pubitemid 27446428)
153. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM,. 2003. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 40: 643-672. (Pubitemid 37491708)
154. Stein DA, Huang CY, Silengo S, Amantana A, Crumley S, Blouch RE, Iversen PL, Kinney RM,. 2008. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J Antimicrob Chemother 62: 555-565.
155. Suksanpaisan L, Cabrera-Hernandez A, Smith DR,. 2007. Infection of human primary hepatocytes with dengue virus serotype 2. J Med Virol 79: 300-307. (Pubitemid 46213194)
156. Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, Aye KM, Aaskov J,. 1997. Risk factors in dengue shock syndrome. Am J Trop Med Hyg 56: 566-572. (Pubitemid 27230081)
157. Urcuqui-Inchima S, Patino C, Torres S, Haenni AL, Diaz FJ,. 2010. Recent developments in understanding dengue virus replication. Adv Virus Res 77: 1-39.
158. van der Schaar HM, Rust MJ, Waarts BL, van der Ende-Metselaar H, Kuhn RJ, Wilschut J, Zhuang X, Smit JM,. 2007. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 81: 12019-12028. (Pubitemid 47623832)
159. Vandenbroucke E, Mehta D, Minshall R, Malik AB,. 2008. Regulation of endothelial junctional permeability. Ann NY Acad Sci 1123: 134-145. (Pubitemid 351431312)
160. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A,. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2-9. (Pubitemid 30049026)
161. Vestweber D,. 2008. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol 28: 223-232. (Pubitemid 351161193)
162. von Moeller H, Basquin C, Conti E,. 2009. The mRNA export protein DBP5 binds RNA and the cytoplasmic nucleoporin NUP214 in a mutually exclusive manner. Nat Struct Mol Biol 16: 247-254.
163. Wang QY, Patel SJ, Vangrevelinghe E, Xu HY, Rao R, Jaber D, Schul W, Gu F, Heudi O, Ma NL, et al. 2009. A small-molecule dengue virus entry inhibitor. Antimicrob Agents Chemother 53: 1823-1831.
164. Warke RV, Becerra A, Zawadzka A, Schmidt DJ, Martin KJ, Giaya K, Dinsmore JH, Woda M, Hendricks G, Levine T, et al. 2008. Efficient dengue virus (DENV) infection of human muscle satellite cells upregulates type I interferon response genes and differentially modulates MHC I expression on bystander and DENV-infected cells. J Gen Virol 89: 1605-1615.
165. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG, Halstead SB,. 1999. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 354: 1431-1434. (Pubitemid 29494755)
166. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, Zhou Y, Doms RW, Diamond MS,. 2005. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 79: 8698-8706. (Pubitemid 40934780)
167. Whitehead SS, Blaney JE, Durbin AP, Murphy BR,. 2007. Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528. (Pubitemid 46925380)
168. Whitehead SS, Falgout B, Hanley KA, Blaney Jr JE, Markoff L, Murphy BR,. 2003. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3â untranslated region is highly attenuated and immunogenic in monkeys. J Virol 77: 1653-1657. (Pubitemid 36055591)
169. WHO. 1997. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: WHO.
170. WHO. 2000. Strengthening implementation of the global strategy for dengue fever/dengue haemorrhagic fever prevention and control. presented at report of the informal consultation. Geneva: WHO.
171. WHO. 2009. Working Group on technical specifications for manufacture and evaluation of dengue vaccines. Geneva, Switzerland, 11-12 May 2009.
172. Williams KL, Zompi S, Beatty PR, Harris E,. 2009. A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci 1171 (Suppl 1): E12-E23.
173. Wu J, Bera AK, Kuhn RJ, Smith JL,. 2005. Structure of the Flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing. J Virol 79: 10268-10277. (Pubitemid 41098568)
174. Wu SF, Lee CJ, Liao CL, Dwek RA, Zitzmann N, Lin YL,. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol 76: 3596-3604. (Pubitemid 34250524)
175. Wu SJ, Hayes CG, Dubois DR, Windheuser MG, Kang YH, Watts DM, Sieckmann DG,. 1995. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am J Trop Med Hyg 52: 468-476.
176. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, et al. 2000. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 6: 816-820. (Pubitemid 30469433)
177. Xu T, Sampath A, Chao A, Wen D, Nanao M, Chene P, Vasudevan SG, Lescar J,. 2005. Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 Å. J Virol 79: 10278-10288. (Pubitemid 41098569)
178. Yamashita T, Unno H, Mori Y, Tani H, Moriishi K, Takamizawa A, Agoh M, Tsukihara T, Matsuura Y,. 2008. Crystal structure of the catalytic domain of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase at a resolution of 1.8 Å. Virology 373: 426-436.
179. Yang KD, Lee CS, Shaio MF,. 1995. A higher production of platelet activating factor in ex vivo heterologously secondary dengue-2 virus infections. Acta Microbiol Immunol Hung 42: 403-407.
180. Yap TL, Xu T, Chen YL, Malet H, Egloff MP, Canard B, Vasudevan SG, Lescar J,. 2007. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J Virol 81: 4753-4765. (Pubitemid 46668672)
181. Yauch LE, Shresta S,. 2008. Mouse models of dengue virus infection and disease. Antiviral Res 80: 87-93.
182. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, et al. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 106: 20435-20439.
183. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J,. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319: 1834-1837. (Pubitemid 351451592)
184. Zellweger RM, Prestwood TR, Shresta S,. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7: 128-139.
185. Zhang S, Vogt MR, Oliphant T, Engle M, Bovshik EI, Diamond MS, Beasley DW,. 2009. Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J Infect Dis 200: 202-205.